Zhejiang Anglikang Pharmaceutical Co Ltd Class A (002940) - Total Liabilities
Based on the latest financial reports, Zhejiang Anglikang Pharmaceutical Co Ltd Class A (002940) has total liabilities worth CN¥1.22 Billion CNY (≈ $179.01 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Zhejiang Anglikang Pharmaceutical Co Ltd Class A - Total Liabilities Trend (2014–2025)
This chart illustrates how Zhejiang Anglikang Pharmaceutical Co Ltd Class A's total liabilities have evolved over time, based on quarterly financial data. See 002940 current assets to equity ratio to evaluate short-term liquidity relative to the company's equity base.
Zhejiang Anglikang Pharmaceutical Co Ltd Class A Competitors by Total Liabilities
The table below lists competitors of Zhejiang Anglikang Pharmaceutical Co Ltd Class A ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Sparekassen Sjaelland-Fyn A/S
CO:SPKSJF
|
Denmark | Dkr30.11 Billion |
|
Corsair Gaming Inc
NASDAQ:CRSR
|
USA | $516.53 Million |
|
Shenzhen Sunnypol Optoelectronics Co Ltd
SHE:002876
|
China | CN¥3.95 Billion |
|
Metals Acquisition Limited
NYSE:MTAL
|
USA | $870.02 Million |
|
Harbin Gloria Pharmaceuticals
SHE:002437
|
China | CN¥735.96 Million |
|
Radius Recycling, Inc.
NASDAQ:RDUS
|
USA | $944.09 Million |
|
ENEFIT GREEN AS
F:I6B
|
Germany | €345.77 Million |
|
Standard Motor Products Inc
NYSE:SMP
|
USA | $1.34 Billion |
Liability Composition Analysis (2014–2025)
This chart breaks down Zhejiang Anglikang Pharmaceutical Co Ltd Class A's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market cap of Zhejiang Anglikang Pharmaceutical Co Ltd.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.84 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.74 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.39 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Zhejiang Anglikang Pharmaceutical Co Ltd Class A's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Zhejiang Anglikang Pharmaceutical Co Ltd Class A (2014–2025)
The table below shows the annual total liabilities of Zhejiang Anglikang Pharmaceutical Co Ltd Class A from 2014 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥1.08 Billion ≈ $158.56 Million |
-7.87% |
| 2024-12-31 | CN¥1.18 Billion ≈ $172.10 Million |
-0.98% |
| 2023-12-31 | CN¥1.19 Billion ≈ $173.80 Million |
+25.03% |
| 2022-12-31 | CN¥949.93 Million ≈ $139.00 Million |
+56.07% |
| 2021-12-31 | CN¥608.64 Million ≈ $89.06 Million |
+8.15% |
| 2020-12-31 | CN¥562.78 Million ≈ $82.35 Million |
+52.72% |
| 2019-12-31 | CN¥368.51 Million ≈ $53.92 Million |
-26.19% |
| 2018-12-31 | CN¥499.27 Million ≈ $73.06 Million |
-2.56% |
| 2017-12-31 | CN¥512.41 Million ≈ $74.98 Million |
+27.93% |
| 2016-12-31 | CN¥400.56 Million ≈ $58.61 Million |
-25.22% |
| 2015-12-31 | CN¥535.63 Million ≈ $78.38 Million |
+4.14% |
| 2014-12-31 | CN¥514.36 Million ≈ $75.27 Million |
-- |
About Zhejiang Anglikang Pharmaceutical Co Ltd Class A
Zhejiang AngLiKang Pharmaceutical CO.,LTD., a pharmaceutical company, engages in manufacturing APIs and pharmaceutical preparations for oral cephalosporins, cardiovascular, and kidney diseases. The company also offers products in the areas of anti-infection, cardiovascular, urinary system (nephropathy), anesthesia and pain, and anti-androgen. The company was founded in 2001 and is based in Shengz… Read more